STEM CELL THERANOSTICS;CAPELLA BIOSCIENCES, INC.; INC.;STEM CELL THERANOSTICS, INC.
发明人:
ARMSTRONG, Christopher,KIM, Kevin,PHAM, Lisa Maria Lucia,PARK, Eunhye,ZHONG, Zhong,HUANG, Guanyi,WU, Joseph,ELMER, Sidney,VISUTHIKRAISEE, Viwat,CADAG, Eithon Michael,FREEMAN, Thomas,LUM, Pek
申请号：
SG11201805375P
公开号：
SG11201805375PA
申请日:
2017.02.03
申请国别(地区):
SG
年份:
2018
代理人:
摘要：
This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
